Welcome to the April/May issue of Pharmafocus, which arrives at a time when established scientific and trade norms are being upended under the current US administration. So, it’s timely that a new report should emerge that examines pharmaceutical trade across Europe and delves into the largest international markets for our industry.

Upheaval of a different kind, and with more potential benefits, can be seen in Europe, with its upcoming European biotechnology law and new Artificial Intelligence Act. Veeva’s Dr Werner Engelbrecht looks at how this type of regulatory momentum could catalyse clinical trial innovation and discusses how compliance can be turned into a competitive advantage (page 18).

The issue also showcases some of the pioneering creativity in pharmaceutical marketing and healthcare communications that was on display at the recent PM Society Awards (page 14). Additionally, we highlight a range of important health challenges, from men’s health to menopause care and mental health, looking at the role the pharmaceutical industry can play as well as exploring some of the wider systemic issues at play.

We hope you enjoy the issue.

The Editorial Team